The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyreti
Phase 3
- Conditions
- Transthyretin Familial Amyloid Polyneuropathy
- Registration Number
- JPRN-jRCT2080221636
- Lead Sponsor
- Pfizer Japan Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
Exclusion Criteria
-Primary amyloidosis and secondary amyloidosis.
-History of liver transplant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TTR stabilization at Week 8 compared with Baseline, as measured by a validated immunoturbidimetric assay.<br>Same as above
- Secondary Outcome Measures
Name Time Method